Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Bicycle Therapeutics (BCYC) Invested Capital (2018 - 2026)

Bicycle Therapeutics (BCYC) has disclosed Invested Capital for 9 consecutive years, with $554.3 million as the latest value for Q1 2026.

  • For Q1 2026, Invested Capital fell 25.13% year-over-year to $554.3 million; the TTM value through Mar 2026 reached $554.3 million, down 25.13%, while the annual FY2025 figure was $610.0 million, 23.09% down from the prior year.
  • Invested Capital hit $554.3 million in Q1 2026 for Bicycle Therapeutics, down from $610.0 million in the prior quarter.
  • Across five years, Invested Capital topped out at $896.2 million in Q2 2024 and bottomed at $220.1 million in Q2 2023.
  • Average Invested Capital over 5 years is $501.2 million, with a median of $416.0 million recorded in 2023.
  • Year-over-year, Invested Capital dropped 29.32% in 2023 and then soared 307.19% in 2024.
  • Bicycle Therapeutics' Invested Capital stood at $270.8 million in 2022, then skyrocketed by 36.98% to $370.9 million in 2023, then skyrocketed by 113.8% to $793.1 million in 2024, then dropped by 23.09% to $610.0 million in 2025, then dropped by 9.12% to $554.3 million in 2026.
  • According to Business Quant data, Invested Capital over the past three periods came in at $554.3 million, $610.0 million, and $618.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.